The Costs of Treatment of Early and ChronicPseudomonas aeruginosaInfection in Cystic Fibrosis Patients
| Autor: | L. Zavataro, Cesare Braggion, V. Boni, A.S. Neri, Silvia Campana, Giovanni Taccetti, F. Trevisan, G. Braccini, V. Galici, Filippo Festini |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
medicine.medical_specialty Cystic Fibrosis medicine.drug_class Antibiotics medicine.disease_cause Ceftazidime Meropenem Cystic fibrosis Clavulanic Acids Pharmacotherapy Cost of Illness Quality of life Ciprofloxacin Internal medicine Humans Ticarcillin Medicine Pseudomonas Infections Pharmacology (medical) Retrospective Studies Antibacterial agent Pharmacology Colistin business.industry Pseudomonas aeruginosa Retrospective cohort study medicine.disease Anti-Bacterial Agents Surgery Infectious Diseases Oncology Child Preschool Chronic Disease Tobramycin Thienamycins business medicine.drug |
| Zdroj: | Journal of Chemotherapy. 21:188-192 |
| ISSN: | 1973-9478 1120-009X |
| DOI: | 10.1179/joc.2009.21.2.188 |
| Popis: | The aim of cystic fibrosis (CF) care is to improve both the life expectancy and quality of life of patients. However, rising costs and limited resources of health services must be taken into account. There are many different antibiotic strategies for therapy of Pseudomonas aeruginosa infection in CF patients. In this 5-year retrospective study we found that the cost of treatment of initial infection is considerably lower than the cost of treating chronic P. aeruginosa infections. The percentage distribution of costs of antibiotic treatment in relationship to the administration route was considerably different between outpatients and inpatients. We observed an increase in antibiotic costs with the age of the patient and the decrease in FEV(1)values. The implementation of early eradication treatment, in addition to decreasing the prevalence of patients chronically infected by P. aeruginosa, might also bring about a notable decrease in costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|